Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Rebuff For Roche’s Valcyte In India, Again

Executive Summary

Roche’s powder formulation for Valcyte (valganciclovir) has failed to secure a patent in India, at least for now, with the patent office seeing no ‘technical advancement’ in the invention.

You may also be interested in...



Medicines Patent Pool Takes Novel Approach With Roche In Valcyte Deal

Roche and the Medicines Patent Pool have signed a five-year deal that will allow developing countries to achieve faster access to the Swiss company’s CMV drug, Valcyte for 90% less.

India dismisses patent on Roche's Valcyte

India has set aside a patent on Roche's Valcyte (valganciclovir) used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.

Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel